It is however tempting to speculate, as previously reported for CTLA-4 (108), that anti-tumor therapies aimed at unleashing KLRG1+ effector cells may target KLRG1+ Treg cells with an overall outcome dictated by the net effect on these two T cell populations. The gene discussed is CTLA4; the disease is neoplasm.